New pill takes aim at Hard-to-Treat prostate cancer
NCT ID NCT07172126
First seen Nov 01, 2025 · Last updated May 31, 2026 · Updated 28 times
Summary
This study tests an experimental pill called TQB3201 for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The drug works by breaking down the androgen receptor, a key driver of cancer growth. The trial involves 291 participants and will first check safety and dosing, then look at how well the drug controls the disease. Because patients will likely need ongoing treatment, this is not a cure but aims to control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Affiliated to Chongqing University
Chongqing, Chongqing Municipality, 400000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 201321, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Fifth Affiliated Hospital of Sun Yat-sen University
Zhuhai, Guangdong, 519000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.